|
시장보고서
상품코드
2101329
복막투석 시장 : 제품별(복막투석 용액 백, 투석기), 치료법별(CAPD), 적응 질환별(말기 신부전), 최종사용자별(병원) - 세계 예측(-2031년)Peritoneal Dialysis Market by Offering (Peritoneal Dialysis Solution Bags, Machines), Modality (Continuous Ambulatory Peritoneal Dialysis Center(CAPD)), Disease Indication (End-Stage Renal Disease), End User (Hospitals)- Global Forecast to 2031 |
||||||
복막투석 시장 규모는 예측 기간 동안 CAGR 6.0%로 확대되어 2026년 100억 4,000만 달러에서 2031년에는 141억 6,000만 달러에 달할 것으로 예측됩니다.
| 조사 범위 | |
|---|---|
| 조사 대상 기간 | 2026-2031년 |
| 기준 연도 | 2025년 |
| 예측 기간 | 2026-2031년 |
| 단위 | 금액(달러) |
| 부문 | 제품 및 서비스, 치료법, 적응 질환, 최종사용자, 지역 |
| 대상 지역 | 북미, 유럽, 아시아태평양, 기타 지역 |
선진국 시장의 유리한 의료 정책 덕분에 복막투석에 대한 접근성이 크게 확대되었습니다. 현재 많은 국가에서 재택 치료에 대한 보험 급여 제도가 제공되고 있기 때문입니다. 대부분의 경우, 미국, 캐나다 및 기타 일부 유럽 국가에서는 환자에게 복막투석이 시설 내 혈액투석보다 비용 대비 효과가 뛰어나고 더 큰 이점을 제공한다는 점을 인정하는 정책이 도입되어 있습니다. 이러한 정책을 통해 복막투석에 수반되는 치료비의 상당 부분이 환급되므로 치료에 대한 장벽이 완화됩니다. 그 결과, 복막투석은 환자에게 더 저렴하고 접근하기 쉬운 치료법이 될 가능성이 있습니다. 또한, 보험 급여 제도는 복막투석의 유연성과 실용성, 특히 자택에서 치료 관리를 희망하는 환자에게 주는 편의성을 고려하여, 의료진이 복막투석을 권장하는 데에도 힘을 실어주고 있습니다. 예를 들어, 미국에서는 메디케어(Medicare)의 ESRD 프로그램이 재택 투석에 대한 보상을 실시함으로써 보급 확대를 촉진하고 있습니다. 마찬가지로 다른 선진국 시장에서도 입원 건수 감소, 환자 예후 개선, 의료 시설의 부담 경감으로 이어지기 때문에 재택 투석 도입이 추진되고 있습니다. 복막투석에 대한 경제적 지원은 고령 환자나 거동 불편 환자에게도 중요하며, 이동 제약이 완화되고 보다 세심한 개별 치료를 받기 쉬워짐으로써 삶의 질 개선으로 이어지고 있습니다.
"말기 신부전(ESRD) 부문이 시장에서 가장 큰 시장 점유율을 차지하고 있으며, 예측 기간 동안 가장 높은 연평균 성장률(CAGR)을 기록할 것으로 전망됩니다."
대부분의 의료 제도에서는 말기 신장질환(ESRD) 환자의 외래 방문 횟수를 줄이고 전체 의료비를 절감하기 위해 재택 투석 옵션을 권장하고 있습니다. 의료 제공자의 입장에서 볼 때, 재택 복막투석 도입으로 시설 내 투석 필요성이 줄어들기 때문에 병원 시설 용량을 확보하고, 시설과 직원 양측에 발생하는 문제를 최소화할 수 있습니다. 또한, 재택 투석은 환자가 자신의 치료를 스스로 관리할 수 있게 줌으로써 삶의 질을 향상시킵니다. 재택 복막투석에는 교통비를 절감할 수 있고, 감염 위험을 줄일 수 있으며, 지속적인 치료를 받기 쉽다는 장점도 있습니다. 이러한 점들로 인해 재택 복막투석은 의료 제도 측면에서도 경제성이 뛰어난 매력적인 치료법이 되고 있습니다.
"재택의료 분야는 가장 큰 시장 점유율을 차지하고 있으며, 예측 기간 동안 가장 높은 연평균 성장률(CAGR)을 기록할 것으로 전망됩니다."
휴대성과 사용 편의성을 갖춘 투석 기기의 보급으로 인해, 재택 환경에서의 치료 안전성과 편의성은 더욱 향상되고 있습니다. 최신 복막투석 장치는 직관적으로 조작할 수 있는 인터페이스, 자동화 기능, 컴팩트한 설계를 갖추고 있어, 환자가 고도의 의학 지식에 크게 의존하지 않고도 비교적 쉽게 사용할 수 있도록 설계되었습니다. 그 결과, 환자는 자립적이고 쾌적한 재택 투석을 수행하기 쉬워졌으며, 의료진에 대한 의존도도 낮아지고 있습니다. 또한, 실시간 모니터링 및 자동 경보 기능 등의 안전 대책도 발전하여, 위험이 발생하기 전에 문제를 조기에 파악하고 적절히 대응할 수 있게 되었습니다. 이러한 혁신으로 인해 환자가 자신의 치료를 관리하는 데 대한 자신감이 높아졌으며, 치료 순응도도 전반적으로 향상되었습니다.
"북미는 예측 기간 동안 상당한 성장률을 보일 것으로 전망됩니다."
2023년 시점에서 아시아태평양이 예측 기간 동안 가장 높은 연평균 성장률(CAGR)을 보일 것으로 예상되는 반면, 시장 점유율 측면에서는 북미가 2025년에 최대 시장 점유율을 차지했습니다. 북미가 복막투석의 최대 지역 시장이 된 한 가지 이유는 해당 지역의 의료진이 이 치료법 관리에 대한 훈련을 받았기 때문입니다. 이를 통해 치료가 필요한 환자들이 자택에서 안전하고 효과적으로 시술을 수행하는 방법에 대해 종합적인 지도를 받을 수 있는 체계가 마련되어 있습니다. 또한, 이러한 전문가들은 효과적인 모니터링을 통해 적시에 개입함으로써 치료 성과를 높이고 합병증을 최소화하고 있습니다. 해당 지역의 전문 연수 프로그램과 지속적인 전문 역량 개발은 고품질의 치료를 더욱 뒷받침하고 있습니다. 의료 종사자들의 이러한 전문성은 북미에서 복막투석의 도입과 보급 성공에 확실히 기여해 왔습니다.
본 보고서에서는 전 세계 복막투석 시장을 조사하여, 시장 개요, 시장 성장에 영향을 미치는 다양한 요인에 대한 분석, 기술 및 특허 동향, 법규제 환경, 사례 연구, 시장 규모 추정 및 전망, 각종 분류·지역/주요 국가별 상세 분석, 경쟁 구도, 주요 기업 개요 등을 정리하고 있습니다.
자주 묻는 질문
목차
제1장 소개
제2장 주요 요약
제3장 주요 인사이트
제4장 시장 개요
제5장 업계 동향
제6장 기술의 진보, AI의 영향, 특허, 혁신, 향후 응용
제7장 규제 상황
제8장 고객 상황과 구매 행동
제9장 복막투석 시장 : 제공별
제10장 복막투석 시장 : 치료법별
제11장 복막투석 시장 : 적응증별
제12장 복막투석 시장 : 최종사용자별
제13장 복막투석 시장 : 지역별
제14장 경쟁 구도
제15장 기업 개요
제16장 조사 방법
제17장 부록
KSM 26.08.03The peritoneal dialysis market is projected to reach USD 14.16 billion by 2031 from USD 10.04 billion in 2026 at a CAGR of 6.0% during the forecast period.
| Scope of the Report | |
|---|---|
| Years Considered for the Study | 2026-2031 |
| Base Year | 2025 |
| Forecast Period | 2026-2031 |
| Units Considered | Value (USD billion) |
| Segments | Offerings, Modality, Disease Indication, End user, and Region |
| Regions covered | North America, Europe, APAC, RoW |
Favorable healthcare policies in developed markets have greatly increased access to peritoneal dialysis, as many now offer reimbursement for home-based treatments. In most cases, the United States, Canada, and several other European countries have implemented policies that acknowledge the cost-effectiveness and greater benefits of peritoneal dialysis over in-center hemodialysis for patients. Such policies reduce barriers to treatment by providing reimbursement for a significant portion of PD-associated treatment costs. This could make PD a much more affordable and accessible form of therapy for patients, and reimbursement programs encourage healthcare providers to recommend PD for its flexibility and practicality, especially for those preferring home management of treatment. For instance, in the United States, Medicare's ESRD program encourages wider adoption by providing reimbursements for home dialysis. Likewise, other developed markets are also following and encouraging home dialysis since it reduces hospital admissions, improves patient outcomes, and reduces burdens on healthcare facilities. The financial support that comes with PD has become a reason for the aged and bedridden patients who have been able to live better as a result of reduced immobilization and enhanced personal care.
"The end-stage renal disease segment holds the largest market share in the global peritoneal dialysis market and is expected to grow at the highest CAGR during the forecast period."
Most healthcare systems promote home dialysis options to reduce hospital visits for end-stage renal disease (ESRD), thereby reducing overall healthcare costs. Health care providers would benefit from home peritoneal dialysis by reducing the need for in-center dialysis, thereby conserving hospital facility capacity and minimizing the problems it poses for both facilities and personnel. Home dialysis will also improve patients' lives by giving them control over their treatment. An added advantage of home-based PD is that it is very economical since it saves transportation costs, minimizes susceptibility to infection, and encourages continuity of care, which makes it an attractive modality for health care systems.
"The home care settings segment accounted for the largest market share in the global peritoneal dialysis market and is expected to grow at the highest CAGR during the forecast period."
Portable, user-friendly dialysis equipment has further improved the safety and ease of treatment for patients in the home setting. Modern peritoneal dialysis machines are well-designed, with intuitive interfaces, automation, and compact size, making them devices that patients can use with relative ease without relying heavily on medical knowledge. Thus, independent, comfortable home-based dialysis has reduced patients' dependence on healthcare professionals. Safety measures have improved with live monitoring and automatic alarms that enhance outcomes best dealt with early, before dangers occur. With those innovations, patients' confidence in managing their care improved, while treatment compliance generally increased.
"North America is expected to witness a substantial growth rate during the forecast period."
The peritoneal dialysis market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa by region. In 2023, the Asia Pacific region is projected to exhibit the highest CAGR during the forecast period. However, North America accounted for the largest market share of the peritoneal dialysis market in 2025. North America is the largest regional market for peritoneal dialysis, partly because healthcare providers in the region have been trained to manage this treatment. This places them in a better position to ensure that patients requiring the treatment receive a holistic education on how to carry out procedures safely and effectively at home. Moreover, these professionals provide timely interventions through effective monitoring, thereby improving outcomes and reducing complications as much as possible. Specialized training programs and ongoing professional development in the region further underpin quality care. Such professionalism among healthcare professionals has indeed contributed to success in the introduction and spread of peritoneal dialysis in North America.
A breakdown of the primary participants (supply-side) for the peritoneal dialysis market referred to in this report is provided below:
- By Company Type: Tier 1:34%, Tier 2: 38%, and Tier 3: 28%
- By Designation: C-level: 26%, Director Level: 35%, and Others: 39%
- By Region: North America: 17%, Europe: 39%, Asia Pacific: 28%, Latin America: 8%, Middle East & Africa: 3%, GCC Countries: 5%
Prominent players in the peritoneal dialysis market are market Vantive (US), Fresenius Medical Care AG (Germany), Mozarc Medical (US), Davita Inc. (US), Becton, Dickinson and Company (US), Utah Medical Products, Inc. (US), Terumo Corporation (Japan), Diaverum AB (Sweden), Medionics (Canada), Newsol Technologies (Canada), Apollo Dialysis Pvt Ltd (India), U.S. Renal Care, Inc. (US), Northwest Kidney Centers (US), Relavo (US), Mitra Industries Pvt Ltd (India), JMS Co., Ltd. (Japan), among others.
Research Coverage
The report evaluates the peritoneal dialysis market and estimates the market size and future growth potential of this market based on various segments, including offerings, modality, disease indication, end user, and region. The report also includes a competitive analysis of the major players in this market, along with company profiles, product offerings, recent developments, and key market strategies.
Reasons to Buy the Report
The report will assist market leaders and new entrants with data on the nearest approximations of revenue numbers for the overall market, the peritoneal dialysis market, and the subsegments. The report will assist stakeholders in understanding the competitive landscape and gain further insights into better positioning their businesses and making appropriate go-to-market strategies. The report helps stakeholders understand the market pulse and provides data on key drivers, barriers, and opportunities in the market.
This report provides insights into the following points:
- Analysis of key drivers Drivers (rising prevalence of chronic kidney diseases, growing prevalence of diabetes and hypertension, and technological advancements and increased investment in R&D) restraints (underutilization of peritoneal dialysis in low-income and lower-middle-income countries (LLMICs)) opportunities (increasing growth opportunities in emerging economies, and surge in demand for home dialysis treatment), and challenges (growing incidence of treated kidney failure, and shortage of skilled nephrologists in low-income and lower-middle-income countries (LLMICs)).
- Product Enhancement/Innovation: Comprehensive details about product launches and anticipated trends in the global peritoneal dialysis market
- Market Development: Thorough knowledge and analysis of the profitable rising markets by offerings, modality, disease indication, end user, and region.
- Market Diversification: Comprehensive information about newly launched products, expanding markets, current advancements, and investments in the global peritoneal dialysis market
- Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings, and capacities of the major competitors in the global peritoneal dialysis market
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.2.1 INCLUSIONS AND EXCLUSIONS
- 1.3 STUDY SCOPE
- 1.3.1 SEGMENTS COVERED
- 1.4 YEARS CONSIDERED
- 1.5 CURRENCY USED
- 1.6 STAKEHOLDERS
- 1.7 LIMITATIONS
- 1.8 SUMMARY OF CHANGES
2 EXECUTIVE SUMMARY
- 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
- 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND START DEVELOPMENTS
- 2.3 DISRUPTIVE TRENDS SHAPING MARKET
- 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
- 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST
3 PREMIUM INSIGHTS
- 3.1 PERITONEAL DIALYSIS MARKET OVERVIEW
- 3.2 NORTH AMERICA: PERITONEAL DIALYSIS MARKET, BY PRODUCT AND COUNTRY
- 3.3 PERITONEAL DIALYSIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
- 3.4 PERITONEAL DIALYSIS MARKET, BY REGION
- 3.5 PERITONEAL DIALYSIS MARKET: DEVELOPED MARKETS VS. EMERGING ECONOMIES
4 MARKET OVERVIEW
- 4.1 INTRODUCTION
- 4.2 MARKET DYNAMICS
- 4.2.1 DRIVERS
- 4.2.1.1 Rising prevalence of chronic kidney diseases
- 4.2.1.2 Growing prevalence of diabetes and hypertension
- 4.2.1.3 Technological advancements and increased investment in R&D
- 4.2.2 RESTRAINTS
- 4.2.2.1 Underutilization of peritoneal dialysis in low-income and lower-middle-income countries (LLMICs)
- 4.2.3 OPPORTUNITIES
- 4.2.3.1 Increasing growth opportunities in emerging economies
- 4.2.3.2 Surge in demand for home dialysis treatment
- 4.2.4 CHALLENGES
- 4.2.4.1 Shortage of skilled nephrologists in low-income and lower-middle-income countries (LLMICs)
- 4.2.4.2 High risk of peritonitis as a barrier to peritoneal dialysis adoption
- 4.2.1 DRIVERS
- 4.3 UNMET NEEDS AND WHITE SPACES
- 4.3.1 UNMET NEEDS IN PATIENT MONITORING DEVICES MARKET
- 4.3.2 WHITE SPACE OPPORTUNITIES
- 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
- 4.4.1 INTERCONNECTED MARKETS
- 4.4.2 CROSS-SECTOR OPPORTUNTIES
- 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS
5 INDUSTRY TRENDS
- 5.1 PORTER'S FIVE FORCES ANALYSIS
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 THREAT OF SUBSTITUTES
- 5.1.3 BARGAINING POWER OF SUPPLIERS
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.2 MACROECONOMIC OUTLOOK
- 5.2.1 INTRODUCTION
- 5.2.2 GDP TRENDS AND FORECAST
- 5.2.3 TRENDS IN GLOBAL PERITONEAL DIALYSIS INDUSTRY
- 5.2.4 TRENDS IN GLOBAL HEALTHCARE & RENAL CARE INDUSTRY
- 5.3 SUPPLY CHAIN ANALYSIS
- 5.4 VALUE CHAIN ANALYSIS
- 5.5 ECOSYSTEM ANALYSIS
- 5.6 PRICING ANALYSIS
- 5.6.1 AVERAGE SELLING PRICE TREND, BY PRODUCT
- 5.6.2 AVERAGE SELLING PRICE OF PERITONEAL DIALYSIS PRODUCTS AND CONSUMABLES, BY KEY PLAYER
- 5.6.3 AVERAGE SELLING PRICE TREND OF PERITONEAL DIALYSIS MACHINES, BY REGION
- 5.7 TRADE ANALYSIS
- 5.7.1 IMPORT SCENARIO (HS CODE 9018)
- 5.7.2 EXPORT DATA (HS CODE 9018)
- 5.8 KEY CONFERENCES & EVENTS, 2026-2027
- 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.10 INVESTMENT AND FUNDING SCENARIO
- 5.11 CASE STUDY ANALYSIS
- 5.11.1 EXPANDING HOME-BASED PERITONEAL DIALYSIS THROUGH REMOTE PATIENT MONITORING
- 5.11.2 ENHANCING HOME PERITONEAL DIALYSIS MANAGEMENT WITH DIGITAL CONNECTIVITY
- 5.11.3 IMPROVING HOME DIALYSIS OUTCOMES THROUGH CONNECTED CARE
- 5.12 IMPACT OF 2025 US TARIFFS - PERITONEAL DIALYSIS MARKET
- 5.12.1 INTRODUCTION
- 5.12.2 KEY TARIFF RATES
- 5.12.3 PRICE IMPACT ANALYSIS
- 5.12.4 IMPACT ON COUNTRIES/REGIONS
- 5.12.4.1 North America
- 5.12.4.2 Europe
- 5.12.4.3 Asia Pacific
- 5.12.5 END-USE INDUSTRY IMPACT
- 5.13 PROCEDURE DATA ANALYSIS
- 5.13.1 PREVALENCE DATA FOR TREATED KIDNEY FAILURE
6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS
- 6.1 KEY EMERGING TECHNOLOGIES
- 6.2 COMPLEMENTARY TECHNOLOGIES
- 6.2.1 REMOTE MONITORING SYSTEMS
- 6.3 TECHNOLOGY/PRODUCT ROADMAP
- 6.3.1 SHORT-TERM (2025-2027) | FOUNDATION & EARLY COMMERCIALIZATION
- 6.3.2 MID-TERM (2027-2030) | EXPANSION & STANDARDIZATION
- 6.3.3 LONG-TERM (2030-2035+) | MASS COMMERCIALIZATION & DISRUPTION
- 6.4 PATENT ANALYSIS
- 6.4.1 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
- 6.5 FUTURE APPLICATIONS
- 6.5.1 AI-ENABLED REMOTE PERITONEAL DIALYSIS MANAGEMENT & PREDICTIVE CARE
- 6.5.2 SMART PERITONEAL DIALYSIS ECOSYSTEMS
- 6.5.3 ADVANCED PERITONEAL DIALYSIS CONSUMABLES & BIOCOMPATIBLE SOLUTIONS
- 6.6 IMPACT OF AI/GEN AI ON PERITONEAL DIALYSIS MARKET
- 6.6.1 TOP USE CASES AND MARKET POTENTIAL
- 6.6.2 CASE STUDIES OF AI IMPLEMENTATION IN PERITONEAL DIALYSIS MARKET
- 6.6.3 INTERCONNECTED ADJACENT ECOSYSTEM AND IMPACT ON MARKET PLAYERS
- 6.6.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN PERITONEAL DIALYSIS MARKET
7 REGULATORY LANDSCAPE
- 7.1 REGIONAL REGULATIONS AND COMPLIANCE
- 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 7.1.2 INDUSTRY STANDARDS
8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
- 8.1 DECISION-MAKING PROCESS
- 8.2 BUYER STAKEHOLDERS AND BUYING EVALUATION CRITERIA
- 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 8.2.2 KEY BUYING CRITERIA
- 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
- 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
- 8.5 MARKET PROFITABILITY
- 8.5.1 REVENUE POTENTIAL
- 8.5.2 COST DYNAMICS
- 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS
9 PERITONEAL DIALYSIS MARKET, BY OFFERING
- 9.1 INTRODUCTION
- 9.2 PERITONEAL DIALYSIS PRODUCTS
- 9.2.1 PERITONEAL DIALYSIS SOLUTION BAGS
- 9.2.1.1 High demand for solutions to boost segmental growth
- 9.2.2 PERITONEAL DIALYSIS MACHINES
- 9.2.2.1 Rising prevalence of chronic diseases in emerging economies to boost adoption
- 9.2.3 PERITONEAL DIALYSIS CATHETERS
- 9.2.3.1 Favorable reimbursement policies to support market growth
- 9.2.4 PERITONEAL DIALYSIS TRANSFER SETS
- 9.2.4.1 Product recalls to limit market growth
- 9.2.5 OTHER PERITONEAL DIALYSIS PRODUCTS
- 9.2.1 PERITONEAL DIALYSIS SOLUTION BAGS
- 9.3 PERITONEAL DIALYSIS SERVICES
- 9.3.1 BETTER PRIVACY AND INCREASED COMFORT OF AT-HOME DIALYSIS TREATMENT TO DRIVE MARKET
10 PERITONEAL DIALYSIS MARKET, BY MODALITY
- 10.1 INTRODUCTION
- 10.2 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD)
- 10.2.1 SUPERIOR CLEARANCE OF HIGH-MOLECULAR-WEIGHT SUBSTANCES TO DRIVE MARKET
- 10.3 AUTOMATED PERITONEAL DIALYSIS (APD)
- 10.3.1 RISK OF RAPID DECLINE IN RESIDUAL RENAL FUNCTIONS TO LIMIT ADOPTION
11 PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION
- 11.1 INTRODUCTION
- 11.2 END-STAGE RENAL DISEASE
- 11.2.1 GROWING GERIATRIC POPULATION AND INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET
- 11.3 ACUTE KIDNEY INJURY
- 11.3.1 INCREASING HOSPITALIZATIONS TO PROPEL MARKET GROWTH
- 11.4 OTHER DISEASES
12 PERITONEAL DIALYSIS MARKET, BY END USER
- 12.1 INTRODUCTION
- 12.2 HOME CARE SETTINGS
- 12.2.1 LOWER COST AND SHORTER HOSPITAL STAYS TO AID MARKET GROWTH
- 12.3 HOSPITALS & INDEPENDENT DIALYSIS CENTERS
- 12.3.1 IMPROVED FACILITIES AND INCREASED GOVERNMENT SUPPORT TO DRIVE MARKET
- 12.4 OTHER END USERS
13 PERITONEAL DIALYSIS MARKET, BY REGION
- 13.1 INTRODUCTION
- 13.1.1 PERITONEAL DIALYSIS PREVALENCE DATA
- 13.1.2 PERITONEAL DIALYSIS PROCEDURE DATA
- 13.2 NORTH AMERICA
- 13.2.1 US
- 13.2.1.1 US to account for largest market share during study period
- 13.2.2 CANADA
- 13.2.2.1 Shortage of dialysis facilities and increased treatment cost to limit market
- 13.2.1 US
- 13.3 EUROPE
- 13.3.1 GERMANY
- 13.3.1.1 Rising number of end-stage renal disease (ESRD) patients to boost market growth
- 13.3.2 UK
- 13.3.2.1 Increased number of new dialysis centers and technological advancements to support market growth
- 13.3.3 FRANCE
- 13.3.3.1 Low cost of peritoneal dialysis and consistent reimbursement policies to drive market growth
- 13.3.4 ITALY
- 13.3.4.1 Increasing research activities and growing patient population with acute renal failure to augment market growth
- 13.3.5 SPAIN
- 13.3.5.1 Favorable reimbursement scenario to boost market growth
- 13.3.6 REST OF EUROPE
- 13.3.1 GERMANY
- 13.4 ASIA PACIFIC
- 13.4.1 JAPAN
- 13.4.1.1 High prevalence of end-stage renal disease (ESRD) and large geriatric population to support market growth
- 13.4.2 CHINA
- 13.4.2.1 Increasing prevalence of diabetes and hypertension to drive market
- 13.4.3 INDIA
- 13.4.3.1 Favorable government initiatives and high prevalence of kidney disease to fuel market growth
- 13.4.4 AUSTRALIA
- 13.4.4.1 Increasing government initiatives about renal care to support market growth
- 13.4.5 SOUTH KOREA
- 13.4.5.1 Growing geriatric population with chronic kidney disease to propel market growth
- 13.4.6 REST OF ASIA PACIFIC
- 13.4.1 JAPAN
- 13.5 LATIN AMERICA
- 13.5.1 BRAZIL
- 13.5.1.1 Brazil to account for largest share of Latin American market during forecast period
- 13.5.2 MEXICO
- 13.5.2.1 Increasing patient population and growing middle class population to boost market growth
- 13.5.3 REST OF LATIN AMERICA
- 13.5.1 BRAZIL
- 13.6 MIDDLE EAST & AFRICA
- 13.6.1 GROWING DEMAND FOR CONVENIENT AND ACCESSIBLE RENAL CARE TO PROPEL GROWTH
- 13.7 GCC COUNTRIES
- 13.7.1 HIGHER DISPOSABLE INCOME AND INCREASED GOVERNMENT HEALTHCARE EXPENDITURE TO PROPEL MARKET GROWTH
14 COMPETITIVE LANDSCAPE
- 14.1 OVERVIEW
- 14.2 KEY PLAYER STRATEGY/RIGHT TO WIN
- 14.3 REVENUE ANALYSIS
- 14.4 MARKET SHARE ANALYSIS
- 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
- 14.5.1 STARS
- 14.5.2 EMERGING LEADERS
- 14.5.3 PERVASIVE PLAYERS
- 14.5.4 PARTICIPANTS
- 14.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
- 14.5.5.1 Company footprint
- 14.5.5.2 Region footprint
- 14.5.5.3 Offering footprint
- 14.5.5.4 Modality footprint
- 14.5.5.5 Disease indication footprint
- 14.5.5.6 End-user footprint
- 14.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
- 14.6.1 PROGRESSIVE COMPANIES
- 14.6.2 RESPONSIVE COMPANIES
- 14.6.3 DYNAMIC COMPANIES
- 14.6.4 STARTING BLOCKS
- 14.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
- 14.6.5.1 Detailed list of key start-up/SME players
- 14.6.5.2 Competitive benchmarking of key startup/SME players
- 14.7 COMPANY VALUATION & FINANCIAL METRICS
- 14.8 BRAND/PRODUCT COMPARISON
- 14.9 COMPETITIVE SCENARIO
- 14.9.1 PRODUCT APPROVALS
- 14.9.2 DEALS
- 14.9.3 EXPANSIONS
- 14.9.3.1 Other developments
15 COMPANY PROFILES
- 15.1 KEY PLAYERS
- 15.1.1 FRESENIUS MEDICAL CARE AG
- 15.1.1.1 Business overview
- 15.1.1.2 Products & services offered
- 15.1.1.3 Recent developments
- 15.1.1.3.1 Deals
- 15.1.1.4 MnM view
- 15.1.1.4.1 Right to win
- 15.1.1.4.2 Strategic choices
- 15.1.1.4.3 Weaknesses & competitive threats
- 15.1.2 VANTIVE
- 15.1.2.1 Business overview
- 15.1.2.2 Products & services offered
- 15.1.2.3 Recent developments
- 15.1.2.3.1 Deals
- 15.1.2.4 MnM view
- 15.1.2.4.1 Right to win
- 15.1.2.4.2 Strategic choices
- 15.1.2.4.3 Weaknesses & competitive threats
- 15.1.3 DAVITA INC.
- 15.1.3.1 Business overview
- 15.1.3.2 Products & services offered
- 15.1.3.3 Recent developments
- 15.1.3.3.1 Deals
- 15.1.3.3.2 Expansions
- 15.1.3.4 Other developments
- 15.1.3.5 MnM view
- 15.1.3.5.1 Right to win
- 15.1.3.5.2 Strategic choices
- 15.1.3.5.3 Weaknesses & competitive threats
- 15.1.4 TERUMO CORPORATION
- 15.1.4.1 Business overview
- 15.1.4.2 Products & services offered
- 15.1.4.3 Recent developments
- 15.1.4.3.1 Product approvals
- 15.1.4.3.2 Deals
- 15.1.4.3.3 Expansions
- 15.1.4.4 MnM view
- 15.1.4.4.1 Right to win
- 15.1.4.4.2 Strategic choices
- 15.1.4.4.3 Weaknesses & competitive threats
- 15.1.5 BECTON, DICKINSON AND COMPANY
- 15.1.5.1 Business overview
- 15.1.5.2 Products & services offered
- 15.1.5.3 Recent developments
- 15.1.5.3.1 Expansions
- 15.1.5.4 MnM view
- 15.1.5.4.1 Right to win
- 15.1.5.4.2 Strategic choices
- 15.1.5.4.3 Weaknesses & competitive threats
- 15.1.6 UTAH MEDICAL PRODUCTS, INC.
- 15.1.6.1 Business overview
- 15.1.6.2 Products & services offered
- 15.1.7 MOZARC MEDICAL
- 15.1.7.1 Business overview
- 15.1.7.2 Products & services offered
- 15.1.8 DIAVERUM AB
- 15.1.8.1 Business overview
- 15.1.8.2 Products & services offered
- 15.1.9 MEDIONICS
- 15.1.9.1 Business overview
- 15.1.9.2 Products & services offered
- 15.1.10 NEWSOL TECHNOLOGIES INC.
- 15.1.10.1 Business overview
- 15.1.10.2 Products & services offered
- 15.1.11 APOLLO DIALYSIS PVT. LTD.
- 15.1.11.1 Business overview
- 15.1.11.2 Products & services offered
- 15.1.12 U.S. RENAL CARE, INC.
- 15.1.12.1 Business overview
- 15.1.12.2 Products & services offered
- 15.1.13 NORTHWEST KIDNEY CENTERS
- 15.1.13.1 Business overview
- 15.1.13.2 Products & services offered
- 15.1.13.3 Recent developments
- 15.1.13.3.1 Deals
- 15.1.13.3.2 Expansions
- 15.1.14 RELAVO
- 15.1.14.1 Business overview
- 15.1.14.2 Products & services offered
- 15.1.15 MITRA INDUSTRIES PVT. LTD.
- 15.1.15.1 Business overview
- 15.1.15.2 Products & services offered
- 15.1.1 FRESENIUS MEDICAL CARE AG
- 15.2 OTHER PLAYERS
- 15.2.1 JMS CO., LTD.
- 15.2.2 AMECATH
- 15.2.3 POLYMEDICURE
- 15.2.4 HUAREN PHARMACEUTICAL
- 15.2.5 AWAK TECHNOLOGIES
- 15.2.6 INNOVATIVE RENAL CARE
- 15.2.7 ROMSONS
- 15.2.8 SSEM MTHEMBU MEDICAL (PTY) LTD.
- 15.2.9 RENAX BIOMEDICAL TECHNOLOGY CO., LTD.
- 15.2.10 ADVIN HEALTH CARE
16 RESEARCH METHODOLOGY
- 16.1 RESEARCH DATA
- 16.1.1 SECONDARY DATA
- 16.1.2 PRIMARY DATA
- 16.2 MARKET SIZE ESTIMATION
- 16.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
- 16.2.2 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS
- 16.2.3 USAGE-BASED MARKET ESTIMATION
- 16.2.4 PRIMARY RESEARCH VALIDATION
- 16.3 GROWTH FORECAST ESTIMATION
- 16.4 DATA TRIANGULATION
- 16.5 STUDY ASSUMPTIONS
- 16.6 RISK ASSESSMENT
- 16.7 RESEARCH LIMITATIONS
17 APPENDIX
- 17.1 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 17.2 CUSTOMIZATION OPTIONS
- 17.3 RELATED REPORTS
- 17.4 AUTHOR DETAILS
